Patient-derived Organoid Model and Circulating Tumor Cells for Treatment Response of Lung Cancer

Launched by THE UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO · Aug 29, 2018

Keywords

ClinConnect Summary

This clinical trial is studying how to create a living biobank of patient-derived organoids from people with lung cancer. Organoids are tiny, lab-grown versions of tumors that can help doctors understand how a patient’s cancer might respond to different treatments. The goal is to gather samples from patients with stage I to III lung cancer to improve future treatment strategies.

To participate in this study, you need to be at least 18 years old and have a diagnosis of lung cancer or related conditions. You should also be planning to receive standard treatment, like medication or surgery. Participants will be asked to fill out a questionnaire about their environmental and lifestyle factors, such as smoking or alcohol use. If you join the study, you will help researchers learn more about lung cancer, which may lead to better treatments for others in the future. The trial is currently looking for volunteers, so if you meet the criteria, you might be able to contribute to this important research.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Read, consented to and signed the IRB-approved informed consent form prior to any study related procedure.
• • Diagnosis of lung cancer or lung mass or lymphadenopathy that will either systemic treatment or tumor resection as part of standard of care
• • Any clinical stage of lung cancer
• • Adult patients ≥18 years of age
• • Able and willing to complete a questionnaire on their environmental/occupational exposures and smoking/alcohol history
• Exclusion Criteria:
• • At the discretion of the treating physician, patient will not be able to fulfill the requirements of the study.